Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Organisation › Details

Immatics Biotechnologies GmbH

Immatics is a clinical-stage biopharmaceutical company spearheading the development of advanced immunotherapies that are active against multiple cancer indications. Based in Tuebingen, Germany, and Houston, Texas, the company has recognized that novel, better and safer targets are the key to developing future cancer immunotherapies. Immatics has revolutionized the identification and qualification of novel, proprietary and tumor-specific peptide antigens (TUMAPs) by developing its world-leading T-cell receptor (TCR) and target discovery platform XPRESIDENT®. TUMAPs significantly expand the target space for immune-oncology as they are not limited to surface proteins, which are the targets of classical antibodies or CAR-T therapies. Immatics believes that, by using its proprietary expertise, it can unlock the significant potential of immune-oncology drugs. Immatics’ pipeline includes several Bispecific TCR and T-cell therapy programs, including ACTolog® and ACTengine®, developed in collaboration through Immatics US with MD Anderson, and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT). By using its world-leading target and TCR discovery expertise, Immatics aims to deliver safer, best-in-class immunotherapies to cancer patients with high medical need in multiple indications. About ACTolog® T-cell therapy The ACTolog® concept is based on the principle of endogenous T-cell therapy pioneered by Professor Cassian Yee, M.D. Unlike tumor-infiltrating lymphocytes, ACTolog® T-cell products are generated from peripheral blood cells with defined target selectivity. Utilizing its proprietary antigen discovery platform XPRESIDENT®, Immatics has created a warehouse of eight cancer targets. From this warehouse, the most suitable targets for each patient’s tumor are identified by analyzing the tumor biomarkers. Up to four personalized T-cell products are then activated and manufactured for each patient by isolation and enrichment of the patient’s endogenous T-cells in vitro. Billions of such activated and specific T-cells are then re-infused into the cancer patient to attack the tumor. *

 

Period Start 2000-09-01 splitoff
  Group Immatics (Group)
  Predecessor University of Tübingen (Eberhard-Karls-Universität)
Product Industry cancer drug
Persons Person Higham, Paul G. (Glycotope 201601– CEO before Immatics 200808–201508 CEO before Ark Therapeutics + GlaxoWellcome)
  Person 2 Reinhardt, Carsten (Immatics 200910– CMO before Micromet 200506– CMO before Roche)
     
Region Region Tübingen
  Country Germany
  Street 15 Paul-Ehrlich-Str.
  City 72076 Tübingen
  Tel +49-7071-5397-0
    Address record changed: 2018-07-24
     
Basic data Employees C: 51 to 100 (2015-08-26)
     
    * Document for �About Section�: Immatics Biotechnologies GmbH. (8/21/17). "Press Release: Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse". Houston, TX & Tübingen.
     
   
Record changed: 2019-01-08

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Immatics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top